Pfizer plans to seek Emergency Use Authorization in the U-S for its COVID-19 vaccine candidate “within days”.
It comes as the company announced a final analysis of its vaccine shows it’s 95% effective.
Pfizer says a review found the vaccine was “well-tolerated” with no serious safety problems.
The company counted 170 cases of COVID-19 among its roughly 43,000 study participants.
Only eight cases were observed among those who received the vaccine.
The remaining 162 cases were observed in the placebo group.
